Volver

Elija su región

Corporate

Europa:

Flaga Albania Albania Flaga Alemania Alemania Flaga Bosnia y Herzegovina Bosnia y Herzegovina Flaga Bulgaria Bulgaria Flaga Croacia Croacia Flaga Cyprus Cyprus Flaga Dinamarca Dinamarca Flaga Eslovaquia Eslovaquia Flaga Eslovenia Eslovenia Flaga España España Flaga Estonia Estonia Flaga Gran bretaña Gran bretaña Flaga Hungría Hungría Flaga Italia Italia Flaga Kosovo Kosovo Flaga Letonia Letonia Flaga Lituania Lituania Flaga Luxemburgo Luxemburgo Flaga Macedonia Macedonia Flaga Montenegro Montenegro Flaga Polonia Polonia Flaga Portugal Portugal Flaga República Checa República Checa Flaga Rumania Rumania Flaga Serbia Serbia Flaga Suecia Suecia Flaga Suiza Suiza Flaga Turquía Turquía

Asia:

Flaga Hong Kong Hong Kong Flaga Kuwait Kuwait Flaga Liban Liban Flaga UAE UAE

Africa:

Flaga RPA RPA
Contacto

¡Contáctanos hoy mismo!

¿Quieres saber más sobre nuestros servicios? Completa el formulario a continuación y nos pondremos en contacto contigo lo antes posible para proporcionarte toda la información necesaria y responder a tus preguntas.

    Le informamos que estos datos serán incorporados al sistema de tratamiento titularidad de SEVIBE CELLS S.L. con CIF B64646912 y domicilio social sito en Av. Parc Tecnològic nº3, 08290, Cerdanyola del Vallès, con la finalidad de atender sus consultas y remitirle información relacionada que pueda ser de su interés.

    Imagen

    Información del Grupo FamiCord
    Última actualización: 06.2026

    Más información en: https://famicord.eu/

    Esta información pertenece al Grupo Famicord (no a Sevibe directamente). Hace referencia a:

    • Uso de progenitores hematopoyéticos de diferentes fuentes:
      • Adipose Tissue = tejido adiposo
      • Apheresis = aféresis
      • Bone Marrow = médula ósea
      • Bone Marrow (Apheresismily donor) = médula ósea (donante por aféresis)
      • Bone Marrow Family = médula ósea familiar
      • Cord Blood = sangre de cordón
      • Cord Tissue = tejido de cordón
      • Placenta blood = sangre de placente
    • A diferentes vías de aplicaciones:
      • Clinical Trial = ensayo clínico
      • Clinical Trial ALSTEM = ensayo clínico ALSTEM
      • Clinical Trial BIOOPA = ensayo clínico BIOOPA
      • Experimental Therapy = terapia experimental
      • Standard Therapy = terapia estándard

    Así mismo, desde los desplegables de la tabla se puede consultar la información sobre el tipo de trasplante, el diagnóstico, el área médica, el año, el país y la edad del receptor.

    Listado del Grupo Famicord

    Imagen
    Lp. Fuente Tipo de trasplante Diagnóstico Área médica Año Terapia País Edad del receptor
    101 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Finland 40
    102 Bone Marrow Family Allogeneic T-Cell Prolymphocytic Leukemia Hematology 2026 Standard Therapy Norway 64
    103 Bone Marrow Family Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 47
    104 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 66
    105 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 68
    106 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Poland 26
    107 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 3
    108 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 62
    109 Bone Marrow Allogeneic Fanconi Anemia Hematology 2026 Standard Therapy Austria 7
    110 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Belgium 12
    111 Bone Marrow Allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy Belgia 3
    112 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 60
    113 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Italy 7
    114 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Italy 4
    115 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 8
    116 Bone Marrow Allogeneic Other Immune System Hematology 2026 Standard Therapy USA 5
    117 Bone Marrow Allogeneic Adrenoleukodystrophy (X-ALD) Hematology 2026 Standard Therapy Czechia 5
    118 Bone Marrow Allogeneic Wiskott-Aldrich Syndrome Hematology 2026 Standard Therapy Germany 19
    119 Bone Marrow Allogeneic Wiskott-Aldrich Syndrome Hematology 2026 Standard Therapy USA 11
    120 Bone Marrow Allogeneic Serum Amyloid A (SAA) Hematology 2026 Standard Therapy Austria 16
    121 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy France 32
    122 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 16
    123 Bone Marrow Allogeneic Other Malignancy Hematology 2026 Standard Therapy France 5
    124 Bone Marrow Allogeneic Mixed type Leukemia Hematology 2026 Standard Therapy Poland 1
    125 Bone Marrow Allogeneic OIID, Chronic Granulomatous Disease CGD Hematology 2026 Standard Therapy Germany 2
    126 Bone Marrow Allogeneic GATA2 deficiency Hematology 2026 Standard Therapy Belgium 12
    127 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 48
    128 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 47
    129 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 80
    130 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy United Kingdom 15
    131 Bone Marrow Allogeneic Severe Aplastic Anemia / AA Amyloidosis Hematology 2026 Standard Therapy United Kingdom 24
    132 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Turkey 8
    133 Bone Marrow Allogeneic SCID Severe Combined Immunodeficiency Hematology 2026 Standard Therapy Poland 1
    134 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 58
    135 Bone Marrow Allogeneic Pure Red Cell Aplasia Hematology 2026 Standard Therapy USA 29
    136 Bone Marrow Allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy USA 19
    137 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy France 21
    138 Bone Marrow Allogeneic B-thalassemia Hematology 2026 Standard Therapy Netherlands 15
    139 Bone Marrow Allogeneic Very Severe Aplastic Anemia Hematology 2026 Standard Therapy Slovakia 31
    140 Bone Marrow Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy Austria 3
    141 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 12
    142 Bone Marrow Allogeneic Diamond Blackfan Anemia Hematology 2026 Standard Therapy Slovakia 9
    143 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Brazil 62
    144 Bone Marrow Allogeneic Griscelli syndrome type 2 Hematology 2026 Standard Therapy Canada 39
    145 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy France 47
    146 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 21
    147 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Hungary 10
    148 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 70
    149 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 6
    150 Bone Marrow Allogeneic Acute Myelogenous Leukemia CR2 Hematology 2026 Standard Therapy Spain 9
    151 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy France 7
    152 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Hungary 23
    153 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy USA 8
    154 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy USA 20
    155 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 1
    156 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy USA 13
    157 Bone Marrow Allogeneic Severe Combined Immunodeficiency Hematology 2026 Standard Therapy USA 2
    158 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Italy 3
    159 Bone Marrow Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 26
    160 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Hungary 9
    161 Bone Marrow Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy Spain 61
    162 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 2
    163 Bone Marrow Allogeneic Other Leukaemia Hematology 2026 Standard Therapy France 1
    164 Bone Marrow Allogeneic – Hematology 2026 Standard Therapy Germany 16
    165 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Belarus 2
    166 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 11
    167 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    168 Apheresis Autologous Plasmablastic Lymphoma Hematology 2026 Standard Therapy Germany 69
    169 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    170 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 54
    171 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 67
    172 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 68
    173 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 69
    174 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 66
    175 Apheresis Allogeneic Fanconi Anemia Hematology 2026 Standard Therapy Germany 4
    176 Apheresis Allogeneic Leukemia T-PLL Hematology 2026 Standard Therapy Norway 64
    177 Apheresis Allogeneic T-cell NHL Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 46
    178 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 60
    179 Apheresis Allogeneic MM, Myeloma Multiplex Hematology 2026 Standard Therapy Poland 48
    180 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Norway 29
    181 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 27
    182 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 34
    183 Apheresis Allogeneic Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) Hematology 2026 Standard Therapy Poland 55
    184 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 11
    185 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Norway 59
    186 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
    187 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 62
    188 Apheresis Allogeneic 2nd Myelodysplastic Syndrome Hematology 2026 Standard Therapy Netherlands 67
    189 Apheresis Allogeneic Acute Myelomonocytic Leukemia (AMML) Hematology 2026 Standard Therapy Ukraine 44
    190 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Portugal 59
    191 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 54
    192 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 67
    193 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 47
    194 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Hungary 42
    195 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 67
    196 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2026 Standard Therapy USA 66
    197 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 59
    198 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 52
    199 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 57
    200 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 56